1. /
  2. About us /
  3. Our people and structure /
  4. Our people /
  5. Danielle Horyniak

Dr Danielle Horyniak

Honorary Staff member

Dr Danielle Horyniak

Background

Danielle is a Senior Research Officer in the Behaviours and Health Risks Program. Drawing on over 15 years of experience in epidemiology, social sciences and policy, Danielle conducts mixed-methods research addressing the social and structural determinants of health for migrant populations.

Her current priority areas are examining the health impacts of deportation policy and practice and understanding and responding to substance use among migrant and refugee young people. Danielle has also conducted research into illicit drug use and related harms, COVID-19, HIV, sexual and reproductive health, and tuberculosis. Danielle holds a Bachelor of Biomedical Science (Hons) and a PhD in Epidemiology, both from Monash University, and undertook post-doctoral research with the Division of Global Public Health, University of California San Diego.

In 2018–19, Danielle was selected into the inaugural cohort of the Australian Science Policy Fellowship Program, through which she worked with the Commonwealth Attorney-General's Department on elder abuse and human rights policy.

Qualifications

  • 2014: PhD, Monash University
  • 2006: BBiomedSci (Hons), Monash University

Appointments

  • Adjunct Research Fellow, School of Public Health & Preventive Medicine, Monash University
  • Member, Monash Migration and Inclusion Centre Next Generation Network

Awards

  • 2018: Ian Potter Foundation Travel Grant
  • 2016: Early Career Investigator Travel Award, College of Problems on Drug

Positions

  • 2021: Senior Research Officer (NHMRC Early Career Research Fellow), Burnet Institute
  • 2015 – 2020: Research Officer

Reports + Policy Briefs

2021 (1)

Reports and other work

  • The Optimise Study: Vaccine preparedness

    This report focuses on:<br/>• Attitudes towards COVID-19 vaccines<br/>• Concerns about the vaccines<br/>• Information needs regarding COVID-19 vaccines and the rollout strategy<br/>

    The Optimise Study: Vaccine preparedness
On this page